innotion.e's aack of look at abbvie buying immunogen for its ovarian cancer dru immun immunogen's beenere but this is more about abbvie losing exclusivity on big drugs an immuno ges prospects. only eli lilly with it blockbuster diabetes and weight loss drug alonwith alzheimer's formulation seems to be doig anhing b buying compans with. so-calleblockbuster products. homegrown what we want. finally the medical device business. crushed during covid when people decided to hold off on all sorts of non-urgent surgerie the strange thing is they're still lding f. the numbers ner came back. very hard to figure. whatever the case,ealth care group seems like a ptty unlikely candidate to help the bullish cause. i li to y there'always hy. prome to t to find it just for you right here on "mad money." i'm jim cramer. i'm jim cramer. see you tomorrow. "last call" starts now. ♪ >>> right now on "last call" -- opec plus whiplash. a critical meeting leaving heads spinning over prices. we'll try to make sense of it all. a november to remember. an epic month for wrapping up your money is december gearing u

immunogen. >> yeah.ke, because they made, i think, promises for those of us who have lost relatives of cancer that i felt were unfair. but they have ovarian, which is just horrendous. good for them. >> well, abbvie is a believer, jim. >> they need something, abbvie. >> premium, as you see, over where the stock was. and that's, again, let's go back to the spring when the stock was far, far lower, but then moved up dramatically on that positive trial data. they do say, as you saw, accretive to eps in 2027. >>> i want to move on. >> if they've got it, it's unbelievable. i don't want to -- this is so needed. so, let's -- good for them. >> i want to move on to a deal that was reported in the "wall street journal" yesterday as a possibility and that is cigna and humana. "the journal" did not actually specify structure of any kind, but they did indicate cash and stock transaction that many assume would involve cigna being the larger of the two buying humana. spoke to a number of large shareholders, well, at lea

the desired gene, for example, in the gel for butterfly children , the associated viruses are low-immunogeniching very foreign and does not fight them too much. the virus is also disarmed, removing the ability to cause disease from its genome; on the contrary, a package for the body is built in, like beads stringing the right one sequence of nucleotides. they place this gene inside the shell of the copsid that has grown into the virus. getting to the patient, he uses his innate ability to penetrate cells; he was infectious in the past and leaves a saving section of dna there. all this sounds simple, but each of the stages described was the result of many years of development, which is why the cost of such treatment is exorbitant, reaching several billion rubles. several drugs have already reached clinical practice. in some cases, they are purchased state, but still parents regularly report situations where they have to collect money from scratch. in the garmaev family from buryatia, daughter adisa was born with spinal muscular atrophy, abbreviated as sma; this disease lacks a gene that is nec